| 000 | 01754 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250515203528.0 | ||
| 264 | 0 | _c20110527 | |
| 008 | 201105s 0 0 eng d | ||
| 022 | _a1573-0646 | ||
| 024 | 7 |
_a10.1007/s10637-009-9383-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhou, Qing | |
| 245 | 0 | 0 |
_aA phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. _h[electronic resource] |
| 260 |
_bInvestigational new drugs _cApr 2011 |
||
| 300 |
_a340-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article | ||
| 650 | 0 | 4 | _a2-Methoxyestradiol |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aDemography |
| 650 | 0 | 4 | _aDogs |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEstradiol _xadministration & dosage |
| 650 | 0 | 4 |
_aEstrenes _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xblood |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aSpecies Specificity |
| 700 | 1 | _aGustafson, Daniel | |
| 700 | 1 | _aNallapareddy, Sujatha | |
| 700 | 1 | _aDiab, Sami | |
| 700 | 1 | _aLeong, Stephen | |
| 700 | 1 | _aLewis, Karl | |
| 700 | 1 | _aGore, Lia | |
| 700 | 1 | _aMessersmith, Wells A | |
| 700 | 1 | _aTreston, Anthony M | |
| 700 | 1 | _aEckhardt, S Gail | |
| 700 | 1 | _aSidor, Carolyn | |
| 700 | 1 | _aCamidge, D Ross | |
| 773 | 0 |
_tInvestigational new drugs _gvol. 29 _gno. 2 _gp. 340-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10637-009-9383-9 _zAvailable from publisher's website |
| 999 |
_c19461438 _d19461438 |
||